Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats

N. Hotta, N. Koh, F. Sakakibara, J. Nakamura, Y. Hamada, Keiji Naruse, H. Sasaki, K. Mizuno, A. Matsubara, H. Kakuta, H. Fukasawa, N. Sakamoto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

To determine the effect of an aldose reductase inhibitor, SNK-860, on the worsening of the electroretinogram (ERG) during a diabetic state, rats with streptozotocin-induced diabetes were administered SNK-860 (1 or 4 mg kg-1 orally) daily for 4 weeks. The effectiveness of SNK-860 in prolonging the peak latencies of oscillatory potentials in the b-wave of the electroretinogram of diabetic rats varied between these different waveform components (designated O1, O2 and O3). SNK-860 (4 mg kg-1 day-1) either completely or partially prevented the prolonged peak latencies at O1 and Σ(O1 + O2 + O3). The drug failed to shorten the latency of the O2 and O3 components, and produced only a modest reduction in retinal levels of sorbitol and fructose, with no increase in myo-inositol. There was a significant correlation between the state of the ERG (components O1 and Σ(O1 + O2 + O3)) and the retinal levels of sorbitol and fructose (P <0.01), but not of myo-inositol. It is concluded that a better understanding of the mechanism by which SNK-860 acts may provide new insight into the pathogenesis of hyperglycaemic retinal dysfunction and help to establish effective therapy for diabetic retinopathy.

Original languageEnglish
Pages (from-to)981-989
Number of pages9
JournalExperimental Physiology
Volume80
Issue number6
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Aldehyde Reductase
Sorbitol
Inositol
Fructose
Experimental Diabetes Mellitus
Diabetic Retinopathy
fidarestat
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Physiology

Cite this

Hotta, N., Koh, N., Sakakibara, F., Nakamura, J., Hamada, Y., Naruse, K., ... Sakamoto, N. (1995). Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats. Experimental Physiology, 80(6), 981-989.

Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats. / Hotta, N.; Koh, N.; Sakakibara, F.; Nakamura, J.; Hamada, Y.; Naruse, Keiji; Sasaki, H.; Mizuno, K.; Matsubara, A.; Kakuta, H.; Fukasawa, H.; Sakamoto, N.

In: Experimental Physiology, Vol. 80, No. 6, 1995, p. 981-989.

Research output: Contribution to journalArticle

Hotta, N, Koh, N, Sakakibara, F, Nakamura, J, Hamada, Y, Naruse, K, Sasaki, H, Mizuno, K, Matsubara, A, Kakuta, H, Fukasawa, H & Sakamoto, N 1995, 'Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats', Experimental Physiology, vol. 80, no. 6, pp. 981-989.
Hotta, N. ; Koh, N. ; Sakakibara, F. ; Nakamura, J. ; Hamada, Y. ; Naruse, Keiji ; Sasaki, H. ; Mizuno, K. ; Matsubara, A. ; Kakuta, H. ; Fukasawa, H. ; Sakamoto, N. / Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats. In: Experimental Physiology. 1995 ; Vol. 80, No. 6. pp. 981-989.
@article{bd40fcb863a044a69818dfbfdc414473,
title = "Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats",
abstract = "To determine the effect of an aldose reductase inhibitor, SNK-860, on the worsening of the electroretinogram (ERG) during a diabetic state, rats with streptozotocin-induced diabetes were administered SNK-860 (1 or 4 mg kg-1 orally) daily for 4 weeks. The effectiveness of SNK-860 in prolonging the peak latencies of oscillatory potentials in the b-wave of the electroretinogram of diabetic rats varied between these different waveform components (designated O1, O2 and O3). SNK-860 (4 mg kg-1 day-1) either completely or partially prevented the prolonged peak latencies at O1 and Σ(O1 + O2 + O3). The drug failed to shorten the latency of the O2 and O3 components, and produced only a modest reduction in retinal levels of sorbitol and fructose, with no increase in myo-inositol. There was a significant correlation between the state of the ERG (components O1 and Σ(O1 + O2 + O3)) and the retinal levels of sorbitol and fructose (P <0.01), but not of myo-inositol. It is concluded that a better understanding of the mechanism by which SNK-860 acts may provide new insight into the pathogenesis of hyperglycaemic retinal dysfunction and help to establish effective therapy for diabetic retinopathy.",
author = "N. Hotta and N. Koh and F. Sakakibara and J. Nakamura and Y. Hamada and Keiji Naruse and H. Sasaki and K. Mizuno and A. Matsubara and H. Kakuta and H. Fukasawa and N. Sakamoto",
year = "1995",
language = "English",
volume = "80",
pages = "981--989",
journal = "Experimental Physiology",
issn = "0958-0670",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats

AU - Hotta, N.

AU - Koh, N.

AU - Sakakibara, F.

AU - Nakamura, J.

AU - Hamada, Y.

AU - Naruse, Keiji

AU - Sasaki, H.

AU - Mizuno, K.

AU - Matsubara, A.

AU - Kakuta, H.

AU - Fukasawa, H.

AU - Sakamoto, N.

PY - 1995

Y1 - 1995

N2 - To determine the effect of an aldose reductase inhibitor, SNK-860, on the worsening of the electroretinogram (ERG) during a diabetic state, rats with streptozotocin-induced diabetes were administered SNK-860 (1 or 4 mg kg-1 orally) daily for 4 weeks. The effectiveness of SNK-860 in prolonging the peak latencies of oscillatory potentials in the b-wave of the electroretinogram of diabetic rats varied between these different waveform components (designated O1, O2 and O3). SNK-860 (4 mg kg-1 day-1) either completely or partially prevented the prolonged peak latencies at O1 and Σ(O1 + O2 + O3). The drug failed to shorten the latency of the O2 and O3 components, and produced only a modest reduction in retinal levels of sorbitol and fructose, with no increase in myo-inositol. There was a significant correlation between the state of the ERG (components O1 and Σ(O1 + O2 + O3)) and the retinal levels of sorbitol and fructose (P <0.01), but not of myo-inositol. It is concluded that a better understanding of the mechanism by which SNK-860 acts may provide new insight into the pathogenesis of hyperglycaemic retinal dysfunction and help to establish effective therapy for diabetic retinopathy.

AB - To determine the effect of an aldose reductase inhibitor, SNK-860, on the worsening of the electroretinogram (ERG) during a diabetic state, rats with streptozotocin-induced diabetes were administered SNK-860 (1 or 4 mg kg-1 orally) daily for 4 weeks. The effectiveness of SNK-860 in prolonging the peak latencies of oscillatory potentials in the b-wave of the electroretinogram of diabetic rats varied between these different waveform components (designated O1, O2 and O3). SNK-860 (4 mg kg-1 day-1) either completely or partially prevented the prolonged peak latencies at O1 and Σ(O1 + O2 + O3). The drug failed to shorten the latency of the O2 and O3 components, and produced only a modest reduction in retinal levels of sorbitol and fructose, with no increase in myo-inositol. There was a significant correlation between the state of the ERG (components O1 and Σ(O1 + O2 + O3)) and the retinal levels of sorbitol and fructose (P <0.01), but not of myo-inositol. It is concluded that a better understanding of the mechanism by which SNK-860 acts may provide new insight into the pathogenesis of hyperglycaemic retinal dysfunction and help to establish effective therapy for diabetic retinopathy.

UR - http://www.scopus.com/inward/record.url?scp=0028829595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028829595&partnerID=8YFLogxK

M3 - Article

C2 - 8962712

AN - SCOPUS:0028829595

VL - 80

SP - 981

EP - 989

JO - Experimental Physiology

JF - Experimental Physiology

SN - 0958-0670

IS - 6

ER -